ICH E6(R3) made Quality Tolerance Limits a formal clinical trial requirement in 2023. Sponsors must define thresholds that indicate systematic quality issues before the trial starts. Most clinical QMS systems are not built to track QTLs in real time.
21 CFR 211.192 requires an Annual Product Review for every batch manufactured in a calendar year. Most pharma QMS systems can't answer the trend question without a manual spreadsheet exercise first. The report is a symptom of the data problem underneath it.
In pharmaceutical manufacturing, a batch that meets specs is not evidence that no deviation occurred. Process deviation and out-of-spec are different events with different investigation requirements. FDA 483 observations routinely cite teams that confuse the two.
GDP compliance is treated as a logistics problem until FDA or a Notified Body requests distribution records. Temperature excursion management, qualified distribution partners, and continuous monitoring records are quality requirements, not logistics preferences.
FDA's QMSR replaced the QSR on Feb 2, 2026. ISO 13485:2016 is now federal law. Internal audits and management reviews are now open to FDA inspection. Complete compliance guide: https://t.co/hBZJhXUVVq
Old way: CAPA lives in a spreadsheet, action items get lost, root cause is vague, closure takes months. New way: automated workflows, real-time status, linked nonconformances, closed in days. Book a demo β https://t.co/xLJJtGLpLr
Most lean kaizen events do not go through ISO 9001 Clause 6.3. The process changes. The SOP does not. A year later the procedure describes something nobody does. Lean finds the problem. ISO 9001 requires the fix to survive in the system. Most skip the second step.
QMSR requires quality agreements for outsourced manufacturing steps. Commercial contracts do not substitute. Quality agreements must define change control, validation, and adverse event reporting responsibilities. FDA requests them as initial inspection documents.
Most manufacturing sites run MES and QMS as separate systems. Batch records in MES. Deviations in QMS. They rarely share the same event ID. A batch deviation closes in QMS while the MES record still shows an open exception. Two systems, two realities.
FDA finalized its Computer Software Assurance guidance on Feb 3, 2026. Risk-based critical thinking replaces documentation-heavy CSV. What changed and how to implement it: https://t.co/8WCr2qLHzA
Receiving inspection that doesn't feed back into supplier risk scoring isn't inspection β it's sorting. The value is in the trend: same supplier, same defect, same process step. That pattern is what your quality system should surface automatically.
Manufacturing quality shouldn't live in spreadsheets. Cloudtheapp eQMS connects every quality process, audits, CAPA, supplier quality, calibration, and more on one AI-powered platform. Built for manufacturers. Watch: https://t.co/1RJo9f2QCS
Most eQMS budget requests fail because they speak quality language, not finance language. Here is the 5-driver ROI framework that gets CFO approval: https://t.co/lf8mOI8up6
FDA 21 CFR 211.84 requires identity testing on at least one sample per lot for incoming materials. A label check doesn't satisfy it. Most receiving inspection programs have the form. Few have the traceability chain that holds up at inspection.
Most SOPs have a periodic review due date in the header. Most regulated facilities have no system that triggers it. When the SME who owned the review leaves, the SOP stays approved and the review never happens. That is a document control finding waiting to occur.
If your QMS disappeared tomorrow, how long would it take to rebuild traceability from raw materials to finished product? A week? A month? That answer tells you exactly how mature your quality infrastructure really is.
EU MDR requires a Summary of Safety and Clinical Performance for Class III and implantable devices. Most teams confuse it with the PSUR. The SSCP is patient-facing: clinical outcomes in plain language, known residual risks, and updated annually in EUDAMED.
Lean kaizen reduces process variation. ISO 9001 requires documented change control for process modifications. Most Lean deployments treat kaizen improvements as exempt from change control. FDA has cited this gap in pharmaceutical and medical device manufacturers.
Under QSR, FDA couldn't request your internal audit reports. Under QMSR (Feb 2026), they can. Every undocumented finding, every unfixed gap in your audit records is now visible to investigators. Is your internal audit program defensible?
Most pharma and medical device teams run QC and QMS in separate systems. That gap is where FDA warning letters come from. What quality control software must do in regulated industries: https://t.co/4z1GLki6w8